Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM17 in Healthy Volunteers and Atopic Dermatitis
NCT07103369Phase 1Completed
- Sponsor
- SinoMab BioScience Limited
- Start
- Nov 2023
- Primary completion
- Mar 2025
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SM17 in atopic dermatitis (AD) (7 arms), sponsored by SinoMab BioScience Limited. Primary endpoints: Incidence of treatment emergent Adverse Events in each cohort (Ph1a), Incidence of treatment emergent Adverse Events in MD cohort (Ph1a) and 1 more. Started Nov 2023; status: completed.
02
Drugs
SM17
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07103369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07103369.